Golden Ten Data reported on June 3 that BioNTech SE (BNTX.O) continued to rise about 8.5% to $122.7. The stock rose more than 18% yesterday. On the news side, Squibb announced that it has reached a licensing agreement with BioNTech for a new generation of anti-cancer drug BNT327, with milestone payments of up to $11.1 billion. Truist Securities raised its price target on BioNTech to $155 from $151, maintaining a "buy" rating.

On September 10, a federal judge in Texas dismissed a securities class action against the operator of the Decentralized Finance project Bancorprotocol. Judge Robert Pitman agreed with the judge's opinion, ruling that the plaintiffs failed to demonstrate that US courts have jurisdiction over foreign defendants.